Quanterix Corporation (QTRX)
QTRX moved a median of -0.21% 30 minutes after news, and -0.24% by the close. How QTRX actually reacts to news — the realized, point-in-time move the market made, measured across 657 labeled events over the last three years with zero look-ahead.
QTRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 654 |
| 30-min | -0.21% | 46% | 654 |
| 60-min | -0.07% | 49% | 654 |
| to close | -0.24% | 46% | 651 |
| Middle 50% of QTRX reactions | -1.19% to +1.01% |
|---|---|
| Median reaction (30-min) | -0.21% |
| Measured reactions | 657 |
Half of all Quanterix Corporation news events land between -1.19% and +1.01% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How QTRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 20 | +0.07% | 50% | +2.18% |
| Price-target cuts | 10 | -1.54% | 30% | +1.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how QTRX ranks against every other measured name →
That’s how QTRX usually reacts — get an email when it moves on news →Email me when QTRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to QTRX's baseline. Nothing else.
Recent QTRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals | Press release | Business Wire | -0.88% | -2.21% | |
| Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026 | Press release | Business Wire | -1.70% | +1.24% | |
| Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.61% | +6.12% | |
| Quanterix Names Dr. Yuri Fesko Chief Medical Officer | Press release | Business Wire | +0.39% | -1.57% | |
| Form S-8 Quanterix Corp | SEC filing · Form S-8 | SEC EDGAR | -0.20% | +1.59% | |
| Form 10-Q Quanterix Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.86% | — | |
| Form 8-K Quanterix Corp For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | — | |
| Quanterix Names Jim Gute Chief Commercial Officer | Press release | Business Wire | -0.86% | — | |
| Quanterix Releases Financial Results for the Second Quarter of 2026 | Press release | Business Wire | -0.86% | — | |
| Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12 | Press release | Business Wire | +0.79% | +1.32% | |
| Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026 | Press release | Business Wire | +1.47% | -1.07% | |
| Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.51% | +0.13% | |
| Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages | Press release | Business Wire | -3.87% | -3.42% | |
| Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +2.31% | -4.95% | |
| Form 8-K Quanterix Corp For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | -2.26% | |
| Form 8-K Quanterix Corp For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +3.83% | -1.28% | |
| Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer | Press release | Business Wire | +3.83% | -1.28% | |
| Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics | Press release | Business Wire | +1.14% | +8.57% | |
| Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | -0.84% | -0.56% | |
| Form 8-K Quanterix Corp For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | -1.12% | |
| Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.37% | -1.12% | |
| Form 8-K Quanterix Corp For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | +1.77% | |
| Quanterix Announces Planned Transition of Chief Financial Officer | Press release | Business Wire | +1.24% | +1.77% | |
| Form DEFA14A Quanterix Corp | SEC filing · Form DEFA14A | SEC EDGAR | +1.80% | +0.72% | |
| Form 10-Q Quanterix Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -8.57% | -12.70% | |
| Form 8-K Quanterix Corp For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -8.57% | -12.70% | |
| Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows | Press release | Business Wire | +0.29% | -2.95% | |
| Quanterix Releases Financial Results for the First Quarter of 2026 | Press release | Business Wire | -8.57% | -12.70% | |
| Form ARS Quanterix Corp For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.79% | +3.15% | |
| Form DEF 14A Quanterix Corp For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -0.79% | +3.15% | |
| Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026 | Press release | Business Wire | -0.79% | +3.15% | |
| AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology | Press release | Business Wire | +2.87% | +0.57% | |
| Quanterix Debuts Content Innovation Engine at AACR 2026 | Press release | Business Wire | +2.47% | +4.65% | |
| Quanterix Corporation Announces Date of 2026 Annual Meeting | Press release | Business Wire | +0.84% | -3.38% | |
| Form S-8 Quanterix Corp | SEC filing · Form S-8 | SEC EDGAR | -1.17% | -1.75% | |
| Form 10-K Quanterix Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +9.28% | +2.80% | |
| Form 8-K Quanterix Corp For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +9.28% | +2.80% | |
| Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide | Press release | Business Wire | -1.75% | +0.96% | |
| Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025 | Press release | Business Wire | +9.28% | +2.80% | |
| Quanterix to Participate in Upcoming Investor Conferences | Press release | Business Wire | -1.10% | +5.99% | |
| Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 | Press release | Business Wire | +1.86% | -2.37% | |
| Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection | Press release | Business Wire | +3.21% | -1.53% | |
| Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling | Press release | Business Wire | +0.85% | +0.14% | |
| Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.95% | -1.82% | |
| Form S-8 Quanterix Corp | SEC filing · Form S-8 | SEC EDGAR | +0.38% | -7.50% | |
| Form 8-K Quanterix Corp For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +12.56% | +20.48% | |
| Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 | Press release | Business Wire | +12.56% | +20.48% | |
| Form S-8 Quanterix Corp | SEC filing · Form S-8 | SEC EDGAR | +1.48% | -2.06% | |
| Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence | Press release | Business Wire | +5.18% | +0.74% | |
| Form 8-K Quanterix Corp For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +1.02% | +13.07% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the QTRX section they belong to.
Where else QTRX is measured.
QTRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Inovio Pharmaceuticals, Inc. (INO) | 658 | -0.29% | 43% |
| VistaGen Therapeutics, Inc. (VTGN) | 658 | +0.16% | 52% |
| Encompass Health Corporation (EHC) | 656 | +0.01% | 51% |
| DIPLOMAT PHARMACY INC (DPLO) | 654 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Quanterix Corporation's median reaction calculated?
Every labeled QTRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 657 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of QTRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does QTRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.